Antigen Binding Proteins for Beta-Amyloid Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Alzheimer's disease and other β-amyloid-related disorders, such as age-related macular degeneration and glaucoma, are limited in their ability to modify the disease progression and effectively reduce β-amyloid levels, leading to short-term cognitive benefits and no definitive treatment for atrophic age-related macular degeneration or prevention of its progression.
Innovation Solution
Development of therapeutic antigen binding proteins, specifically antibodies or their fragments, that recognize and bind to specific epitopes of β-amyloid peptides, particularly residues 28-35, to neutralize or remove β-amyloid, potentially combined with complement pathway inhibitors to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic therapies are used to treat Alzheimer's disease, then cognitive impairment is alleviated temporarily, but the disease progression is not modified and benefits last only up to 2 years
Solution Approach 1:
The patent extracts and removes β-amyloid peptides from the system using antigen binding proteins (antibodies). The antibodies specifically bind to β-amyloid, facilitating its clearance from the brain, thereby addressing the root cause of disease progression rather than just treating symptoms.
Solution Approach 2:
The antigen binding proteins act as intermediaries between the immune system and β-amyloid deposits. These proteins facilitate the removal of β-amyloid by serving as mediators that bind to the toxic peptides and enable their clearance through physiological pathways.
2Duration of action of moving object
If therapies aim to reduce β-amyloid levels to provide sustained cognitive benefits, then disease progression may be modified, but the ability to effectively reduce β-amyloid levels is currently limited
Solution Approach 1:
The patent employs antibodies with specifically engineered binding parameters optimized for β-amyloid recognition. By modifying antibody structure and binding affinity parameters, the therapy achieves effective β-amyloid clearance and sustained cognitive benefits.
3Reliability
If antigen binding proteins are used to target and neutralize β-amyloid, then sustained cognitive benefits and β-amyloid level reduction are achieved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The antigen binding proteins leverage the body's own immune system mechanisms to clear β-amyloid. Once the antibodies bind to β-amyloid, the body's natural clearance pathways handle the removal, reducing the need for complex external intervention systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antigen binding proteins demonstrate the potential to provide sustained cognitive benefits, reduce β-amyloid levels, and address underlying cellular decline in Alzheimer's disease, as well as prevent or delay vision loss in age-related macular degeneration and glaucoma by effectively targeting and neutralizing β-amyloid.
Implementation Method 1
therapeutic antigen binding proteins, specifically antibodies or their fragments, that recognize and bind to specific epitopes of β-amyloid peptides
Data Source
Figure 1
Figure 2~3
Figure 4A~5D
AI summary
Antigen binding proteins that bind ß-amyloid peptide, in particular human ß-amyloid peptide; methods of treating diseases or disorders characterised by elevated ß- amyloid levels or ß-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterised by elevated ß-amyloid levels or ß-amyloid deposits, including age related macular degeneration and glaucoma type diseases and ß-amyloid dependent cataract formation, with said antigen binding proteins; pharmaceutical compositions comprising said antigen binding proteins; and methods of manufacture.